Complete Approach
Qualified
Problem Solvers
Consulting Services
Our Mission
To characterize your proprietary compounds with the integrative approach to cardiac safety & function. We are here to help you with experimental design, data interpretation, and guidance for the next step in the drug discovery process.
- Published Articles
- Cell-Based Assays
- Isolated Tissue
- In Vivo Models
David Fedida, Ph.D., B.M., B.Ch.
President
Dr. David Fedida is Professor of Anesthesiology, Pharmacology and Therapeutics, at the University of British Columbia, where, for the past ten years he has been actively involved in the discovery and mechanisms of action of Vernakalant as a new treatment for the acute conversion of atrial fibrillation to sinus rhythm.
Dr. Fedida has a major interest in ion currents underlying human cardiac repolarization, and how they affect cardiac rhythmicity. He was the first to identify the human heart potassium current IKur with the KCNA5 gene product, a current which has subsequently become an important atria-selective target for the treatment of atrial fibrillation, and he leads a research group at the University of British Columbia investigating human heart potassium channels and the remodeling of cardiac ion channels in diseases like Long QT syndrome.
Dr. Fedida obtained his B.Sc. and Ph.D from the University of Leeds and his MD from Oxford in the UK, and after postgraduate medical training and positions at universities in Canada and the US, since 1998 he has been at the University of British Columbia in Canada, where he was until recently Associate Head of Anesthesiology, Pharmacology and Therapeutics and Associate Dean Research in the Faculty of Medicine.
Marc Pourrier, Ph.D.
Vice President, Operations
Dr. Pourrier has 15 years of experience in the field of electrophysiology and 7 years in drug discovery. After he obtained an under graduated diploma in Biochemistry in Paris, France, Marc moved to Montreal where he completed his Bachelor of Science at the University of Montreal in Biochemistry and his PhD in Pharmacology under the supervision of Dr. Stanley Nattel.
During his PhD, Marc studied the electrophysiological and molecular properties of voltage gated potassium channels. After graduating in 2004, Marc completed a 1 year post-doctoral fellowship at the Montreal Heart Institute, funded by Wyeth US. In April 2005, Marc joined Cardiome Pharma Corp where he was responsible for carrying out studies on the mechanism of action of the atrial antiarrhythmic drug vernakalant. In 2007, Marc became the group leader, electrophysiology.
In this role, Marc joined the Vernakalant Development Team, in which he played a key role not only in the development, but also in regulatory filling (European approval in 2010) and out licensing to Merck of vernakalant. In 2011-2012, Marc acted as a Discovery Project Lead where he was responsible for the day-to-day operations and for coordinating project activities of multidisciplinary teams.
Partners of IonsGate
InSilicoTrials (https://insilicotrials.com) is the first cloud-based platform that provides healthcare companies with easy-to-use tools to perform computational Modeling and Simulation in drug discovery and development. Simulation is a key factor to cut in vitro and in vivo test costs and shorten the go-to-market of new medicines. This enables pharmaceutical companies and CROs to free resources, do more reseach and in the long run find a higher number of new molecules to treat more diseases.
IonsGate Preclinical Services Inc., Vancouver, British Columbia, Canada, V6T 1Z3